sco-101
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04247256)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ABCG2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04652206 | Phase 1/Phase 2 (Phase 2) | Oct 27, 2020 | Alcedis GmbH, Scandion Oncology A/S |
| NCT04247256 | Phase 1/Phase 2 (Phase 2) | Feb 29, 2020 | Scandion Oncology A/S, TFS Trial Form Support, University of Copenhagen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Scandion Oncology A/S | For profit | 2 | 2 | 1 | 2020 |
| Alcedis GmbH | For profit | 1 | 0 | 1 | 2020 |
| TFS Trial Form Support | For profit | 1 | 0 | 1 | 2020 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1